Highlights
- Market Cap
- $4.07B
- Enterprise Value
- $4.06B
- EPS (TTM)
- $4.67
- PE Ratio
- 21.29
- PEG Ratio
- 0.05
- Total Revenue (TTM)
- $605.49M
- Gross Profit (TTM)
- $362.81M
- EBITDA (TTM)
- $137.31M
- Year Range
- $62.23 - $156.00
- Target Price
- $148.17
- ROA (TTM)
- 17.81%
- ROE (TTM)
- 40.22%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in TransMedics Group, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
TransMedics Group, Inc. (TMDX) has returned -18.28% so far this year and 47.76% over the past 12 months.
TransMedics Group, Inc.
- 1D
- 5.41%
- 1M
- -31.56%
- YTD
- -18.28%
- 6M
- -11.40%
- 1Y
- 47.76%
- 3Y*
- 9.49%
- 5Y*
- 19.93%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since May 2, 2019, TMDX's average daily return is +0.18%, while the average monthly return is +4.44%. At this rate, your investment would double in approximately 1.3 years.
Historically, 55% of months were positive and 45% were negative. The best month was Nov 2023 with a return of +101.9%, while the worst month was Oct 2024 at -47.8%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.
On a daily basis, TMDX closed higher 49% of trading days. The best single day was Nov 7, 2023 with a return of +51.2%, while the worst single day was Oct 29, 2024 at -29.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 10.13% | 8.42% | -31.56% | -18.28% | |||||||||
| 2025 | 8.34% | 12.98% | -11.84% | 36.76% | 38.16% | 5.42% | -11.22% | -3.37% | -2.40% | 17.24% | 11.23% | -16.85% | 95.11% |
| 2024 | 8.67% | -4.86% | -9.39% | 27.31% | 44.91% | 10.43% | -5.55% | 18.14% | -6.58% | -47.79% | 5.78% | -28.09% | -21.01% |
| 2023 | 2.11% | 27.05% | -5.42% | 4.45% | -8.14% | 15.58% | 10.95% | -29.57% | -16.58% | -31.54% | 101.92% | 4.29% | 27.88% |
| 2022 | -17.17% | 16.70% | 45.46% | -22.20% | 39.17% | 7.82% | 28.39% | 28.85% | -19.78% | 15.52% | 28.31% | -0.24% | 222.13% |
| 2021 | 14.47% | 57.55% | 15.60% | -30.80% | -10.69% | 29.41% | -14.04% | 14.59% | 1.25% | -17.10% | -19.65% | -13.07% | -3.72% |
Benchmark Metrics
TransMedics Group, Inc. has an annualized alpha of 32.73%, beta of 1.31, and R² of 0.14 versus S&P 500 Index. Calculated based on daily prices since May 03, 2019.
- This stock captured 247.35% of S&P 500 Index gains and 160.79% of its losses — amplifying both gains and losses, but participating more in upside than downside.
- R² of 0.14 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 32.73%
- Beta
- 1.31
- R²
- 0.14
- Upside Capture
- 247.35%
- Downside Capture
- 160.79%
Return for Risk
Risk / Return Rank
TMDX ranks 67 for risk / return — better than 67% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for TransMedics Group, Inc. (TMDX) and compare them to a chosen benchmark (S&P 500 Index).
| TMDX | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.84 | 0.90 | -0.05 |
Sortino ratioReturn per unit of downside risk | 1.60 | 1.39 | +0.22 |
Omega ratioGain probability vs. loss probability | 1.19 | 1.21 | -0.02 |
Calmar ratioReturn relative to maximum drawdown | 1.21 | 1.40 | -0.19 |
Martin ratioReturn relative to average drawdown | 3.07 | 6.61 | -3.53 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore TMDX risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the TransMedics Group, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the TransMedics Group, Inc. was 73.69%, occurring on Feb 23, 2022. Recovery took 113 trading sessions.
The current TransMedics Group, Inc. drawdown is 43.55%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -73.69% | Mar 23, 2021 | 234 | Feb 23, 2022 | 113 | Aug 5, 2022 | 347 |
| -67.79% | Aug 28, 2024 | 99 | Jan 21, 2025 | — | — | — |
| -65.47% | May 23, 2019 | 205 | Mar 16, 2020 | 228 | Feb 9, 2021 | 433 |
| -61.76% | Jul 19, 2023 | 73 | Oct 30, 2023 | 124 | Apr 29, 2024 | 197 |
| -29.9% | Sep 13, 2022 | 24 | Oct 14, 2022 | 15 | Nov 4, 2022 | 39 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of TransMedics Group, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how TransMedics Group, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for TMDX, comparing it with other companies in the Medical Devices industry. Currently, TMDX has a P/E ratio of 21.3. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for TMDX compared to other companies in the Medical Devices industry. TMDX currently has a PEG ratio of 0.1. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for TMDX relative to other companies in the Medical Devices industry. Currently, TMDX has a P/S ratio of 6.7. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TMDX in comparison with other companies in the Medical Devices industry. Currently, TMDX has a P/B value of 8.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |